Pharmacoeconomics

Pear Therapeutics Announces Publication of Real-World Data Showing Improved Clinical Outcomes with a Subsequent Prescription of reSET-O® for Patients with Opioid Use Disorder

Retrieved on: 
Thursday, September 16, 2021
FDA, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Pear, Therapy, DOI, Publication, Incidence, Patient, Association, Language isolate, Current Medical Research and Opinion, QALY, FDA, PMID, Suicidal ideation, Council, Policy, Safety, Council of Economic Advisers, Doctor of Philosophy, SUD, Smartphone, UDS, Buprenorphine, Pharmacoeconomics, Risk, Veni, vidi, vici, Digital, PDT, Clinical study design, Treatment, Hospital Practice, Policy by press release, Naloxone, Medical Care (journal), Industry, Cognitive behavioral therapy, MD, BA, TAU, Insomnia, MBA, Opioid use disorder, Postgraduate Medicine, Death, Health, JAMA Internal Medicine, Population, OUD, Food and Drug Administration, Journal, Journal of Medical Economics, Pharmaceutical industry, Health insurance, Silviculture, Medical device

91.4% of patients were retained in treatment at the end of the second prescription period (weeks 21-24 of 24).

Key Points: 
  • 91.4% of patients were retained in treatment at the end of the second prescription period (weeks 21-24 of 24).
  • reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD).
  • Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population.
  • Patients with opioid use disorder have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion.

Pear Therapeutics Announces Publication of Cost-Utility Data Showing Quality of Life and Cost Reduction with reSET-O® for the Treatment of Opioid Use Disorder

Retrieved on: 
Wednesday, September 1, 2021
FDA, Data Management, Publishing, Other Health, Technology, Pharmaceutical, Communications, General Health, Mental Health, Clinical Trials, Biotechnology, Science, Software, Other Science, Research, Health, Clinical study design, PDT, Calendar, Digital, Journal of Medical Economics, Current Medical Research and Opinion, Naloxone, Pharmacoeconomics, TAU, Risk, NBA Live 10, Pear, Smartphone, Postgraduate Medicine, BA, Therapy, Council, Safety, Doctor of Philosophy, Policy, JAMA Internal Medicine, Clinical trial, Reading, Council of Economic Advisers, Veni, vidi, vici, Patient, MD, Industry, Opioid use disorder, SUD, QALY, Language isolate, MBA, Insomnia, Depression, FDA, Press release, Population, Journal, Death, Health, Treatment, OUD, Buprenorphine, Food and Drug Administration, Cognitive behavioral therapy, DOI, Life expectancy, Suicidal ideation, Data analysis, COVID-19, Pharmaceutical industry, Medical device

Results of this model showed population-level gains in quality-adjusted life years at a lower cost with reSET-O treatment vs TAU alone.

Key Points: 
  • Results of this model showed population-level gains in quality-adjusted life years at a lower cost with reSET-O treatment vs TAU alone.
  • Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population.
  • Pears second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation.
  • Opioid use disorder: endpoints for demonstrating effectiveness of drugs for medicationassisted treatment guidance for industry.

Sera Prognostics Reports Second Quarter 2021 Financial Results

Retrieved on: 
Monday, August 30, 2021
Company, Pregnancy, Proteomics, Private Securities Litigation Reform Act, MS, Blood, Premature, International Society for Pharmacoeconomics and Outcomes Research, U.S. Securities and Exchange Commission, Form, Protein, Trial of the century, GLOBE, SALT, Anthem, Seizure, Anthem Inc. (album), Efficiency, Physician, Security (finance), Health, Research, Death, Pharmacoeconomics, Sumathi Best Television Current Reporting Award, Intellectual disability, Risk, Learning, International Society, Contract, Disease, Partnership, NICU, Patient, Hearing loss, CEO, Publication, CPT, Preterm birth, FDA, Woman, COVID-19, Cerebral palsy, Prospectus, MD, Health insurance, Pharmaceutical industry, Birth control

SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2021.

Key Points: 
  • SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2021.
  • Anthem is the nations second largest health insurer with about 40 million members nationwide and is a strategic investor in Sera Prognostics.
  • Net loss for the second quarter of 2021 was $6.3 million compared to $4.7 million for the same quarter a year ago.
  • Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.

Aquavit Pharmaceuticals, Inc. Secures Court Order on Compensatory Sanctions Against Counterfeiters for Contempt on Patent and Trademark Infringement Case

Retrieved on: 
Thursday, August 13, 2020
Health, Pharmaceuticals policy, Pharmaceutical industry, Judicial remedies, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Pharmacoeconomics, Disgorgement, Articles, Service industries

The Court agreed with Plaintiff that the Second Circuit's decision in Manhattan Indus., Inc. v. Sweater Bee by Banff, Ltd. supports disgorgement in this case as a form of compensatory relief.

Key Points: 
  • The Court agreed with Plaintiff that the Second Circuit's decision in Manhattan Indus., Inc. v. Sweater Bee by Banff, Ltd. supports disgorgement in this case as a form of compensatory relief.
  • 1989) ("[T]he concept of compensatory relief includes profits derived by the contemnor from violation of a court order."
  • Aquavit Pharmaceuticals, Inc. is a high-tech pharmaceutical company that provides a comprehensive range of innovative pharmaceutical, biotech and medical device technologies.
  • Aquavit Pharmaceuticals, Inc. focuses on personalized medicine to improve patients' health, maximize the efficiency of our medical community, and support the pharmacoeconomics of payers.

Genesis Research Announces the Appointment of New Board Member

Retrieved on: 
Monday, May 11, 2020
Musicians, Musical groups, Record labels, Health informatics, Health Economics, Clinical research, Evidence, Real world evidence, Pharmacoeconomics, Genesis, Draft:International Society for Pharmacoeconomics and Outcomes Research

A Charter Member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Chris served as ISPOR President in 2008-2009.

Key Points: 
  • A Charter Member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Chris served as ISPOR President in 2008-2009.
  • We are pleased to welcome Chris to our Board of Directors at this important next stage in Genesis Research's evolution," stated Steve Arikian, MD, Co-Founder & Chairman of the Board of Genesis Research.
  • Genesis Research is a value demonstration company, powered by Real World Evidence development serving the Life Sciences industry.
  • Genesis Research is a portfolio company of Rallyday Partners.

The American Journal of Managed Care® Announces Inmaculada Hernandez as the Recipient of the 2019 Seema S. Sonnad Emerging Leader in Managed Care Research Award

Retrieved on: 
Friday, November 8, 2019
Oncology, Health, Other Science, Managed care, Research, Science, Pharmaceutical, Pharmaceutical industry, Pharmacoeconomics

As an exemplary leader in the field of managed care, Dr. Hernandez sincerely represents the values that the Seema S. Sonnad Emerging Leader in Managed Care Research Award was founded on, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of AJMC.

Key Points: 
  • As an exemplary leader in the field of managed care, Dr. Hernandez sincerely represents the values that the Seema S. Sonnad Emerging Leader in Managed Care Research Award was founded on, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of AJMC.
  • Hernandezs research program is focused on the intersection of pharmaceutical health services and outcomes research, pharmacoepidemiology, pharmacoeconomics and pharmaceutical policy.
  • Hernandez was recently included on the Forbes 30 Under 30 list as a young leader in health care research.
  • For more information about the Seema S. Sonnad Emerging Leader in Managed Care Research Award, click here.

Pharmacist Interns Present Capstone Projects on Health Outcomes in Partnership with Allergan

Retrieved on: 
Thursday, October 31, 2019
Health, Articles, Human activities, Medical education, Medical education in the United States, Academy of Managed Care Pharmacy, Internship, Pharmacoeconomics, Pharmacoeconomics

The Foundation/Allergan Specialized Summer Internship in Health Outcomes exposes interns to careers in pharmacoeconomics through hands-on application of evidence-based decision-making.

Key Points: 
  • The Foundation/Allergan Specialized Summer Internship in Health Outcomes exposes interns to careers in pharmacoeconomics through hands-on application of evidence-based decision-making.
  • The interns completed research projects that will be presented in poster format at AMCP Nexus 2019, Oct. 29-Nov. 1, in National Harbor, Md.
  • Both interns were placed at Allergan's Global Health Economics and Outcomes Research department in Irvine, Calif., with a rotation at AMCP/Foundation headquarters in Alexandria, Va.
  • The interns are:
    Wilson Haong, Western New England University College of Pharmacy and Health Sciences.

Trio Health and Greenleaf Health Partner to Apply FDA-Level Rigor to Groundbreaking Data Platform

Retrieved on: 
Tuesday, October 1, 2019
MDX, Pharmacoeconomics

WASHINGTON, Oct. 1, 2019 /PRNewswire/ --Trio Health, a leading provider of real-time data on real-world patients, today announced it has entered into an exclusive agreement with Greenleaf Health, a leading Food and Drug Administration (FDA) regulatory consulting firm,to unite in utilizing and validating the data analyses from its groundbreaking Multi-Disease Platform (MDX)technology platform.

Key Points: 
  • WASHINGTON, Oct. 1, 2019 /PRNewswire/ --Trio Health, a leading provider of real-time data on real-world patients, today announced it has entered into an exclusive agreement with Greenleaf Health, a leading Food and Drug Administration (FDA) regulatory consulting firm,to unite in utilizing and validating the data analyses from its groundbreaking Multi-Disease Platform (MDX)technology platform.
  • Trio CEO, Brent Clough, Greenleaf CEO Patrick Ronan, and Greenleaf Principals of Drug and Biological Products, John Jenkins, M.D.
  • and Robert Meyer, M.D., will present the MDX platform at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Conference in Copenhagen, November 4.
  • In turn, the platform offers our life science customers best-in-class speed, data certainty, and unparalleled visibility across the clinical and commercial lifecycle.

ISPOR Europe 2018 Whitepaper

Retrieved on: 
Thursday, July 11, 2019
Contents, Health Economics, Politics of the United States, Economy of the United States, Presidency of Donald Trump, Donald Trump, Pharmacoeconomics, Medicare

DUBLIN, July 11, 2019 /PRNewswire/ -- The "ISPOR Europe 2018 Whitepaper" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 11, 2019 /PRNewswire/ -- The "ISPOR Europe 2018 Whitepaper" report has been added to ResearchAndMarkets.com's offering.
  • The ISPOR 21st Annual European Congress held in Barcelona on 10-14 November.
  • Here, we present some of the hot topics discussed at the event, including:
    The Trump administration's recent proposal to internationally price index Medicare part B products against prices in Europe, and the likely impact on access and expenditure.
  • Throughout the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2018 European Conference in Barcelona, the rising cost of prescription drugs in the US, and Trump's recent plans to introduce international reference pricing to European counterparts, were heavy topics of debate.

Aquavit Pharmaceuticals, Inc. Secures Preliminary Injunction and Restraining Order Against Counterfeiters on Patent and Trademark Infringement Case

Retrieved on: 
Tuesday, April 30, 2019
Health, Articles, Pharmaceutical industry, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Food and Drug Administration, Pharmacoeconomics, Pharmaceutical industry in India

The product label on the back of the box was copied almost identically including Aquavit's product code name AQT-001, and Aquavit's FDA registration number.

Key Points: 
  • The product label on the back of the box was copied almost identically including Aquavit's product code name AQT-001, and Aquavit's FDA registration number.
  • The brief relationship was halted when Aquavit discovered U-Bio Med's fraudulent business practices in 2015.
  • Aquavit Pharmaceuticals, Inc. is a high-tech pharmaceutical company that provides a comprehensive range of innovative pharmaceutical, biotech and medical device technologies.
  • Aquavit Pharmaceuticals, Inc. focuses on personalized medicine to improve patients' health, maximize the efficiency of our medical community, and support the pharmacoeconomics of payers.